Patents by Inventor Avery D. Posey

Avery D. Posey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240228655
    Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.
    Type: Application
    Filed: March 28, 2024
    Publication date: July 11, 2024
    Inventors: Marco RUELLA, Saar GILL, Carl H. JUNE, Avery D. POSEY, Daniel J. POWELL
  • Publication number: 20230331864
    Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.
    Type: Application
    Filed: April 21, 2023
    Publication date: October 19, 2023
    Inventors: Marco RUELLA, Saar GILL, Carl H. JUNE, Avery D. POSEY, Daniel J. POWELL
  • Publication number: 20230312677
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein. The CAR may comprise a mutant CD28 costimulatory domain.
    Type: Application
    Filed: November 16, 2022
    Publication date: October 5, 2023
    Inventors: Avery D. Posey, Sonia Guedan Carrio
  • Publication number: 20230242612
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 3, 2023
    Inventors: Carl H. June, John Scholler, Avery D. Posey, Jr.
  • Patent number: 11673964
    Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 13, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Marco Ruella, Saar Gill, Carl H. June, Avery D. Posey, Daniel J. Powell
  • Patent number: 11597754
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 7, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, John Scholler, Avery D. Posey, Jr.
  • Publication number: 20230052970
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Application
    Filed: October 3, 2022
    Publication date: February 16, 2023
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Patent number: 11535662
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein. The CAR may comprise a mutant CD28 costimulatory domain.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: December 27, 2022
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Avery D. Posey, Sonia Guedan Carrio
  • Publication number: 20220380447
    Abstract: The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) capable of binding tumor-specific isoforms of fibronectin.
    Type: Application
    Filed: October 30, 2020
    Publication date: December 1, 2022
    Inventors: Avery D. POSEY, JR., Tiffany KING
  • Patent number: 11459390
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 4, 2022
    Assignees: Novartis AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20220073639
    Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 10, 2022
    Inventors: Marco RUELLA, Saar GILL, Carl H. JUNE, Avery D. POSEY, Daniel J. POWELL
  • Publication number: 20210371495
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 2, 2021
    Inventors: Carl H. June, John Scholler, Avery D. Posey, JR.
  • Publication number: 20210338733
    Abstract: Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
    Type: Application
    Filed: July 8, 2021
    Publication date: November 4, 2021
    Inventors: Avery D. Posey, Carl H. June
  • Patent number: 11090336
    Abstract: Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: August 17, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Avery D. Posey, Carl H. June
  • Publication number: 20210060071
    Abstract: The present invention includes compositions and methods for treating atherosclerosis. In certain embodiments, atherosclerosis is treated using a chimeric antigen receptor (CAR) T cell specific for modified low-density lipoprotein.
    Type: Application
    Filed: April 26, 2019
    Publication date: March 4, 2021
    Inventors: Avery D. POSEY, Carl H. JUNE, Robert D. SCHWAB
  • Publication number: 20210032661
    Abstract: The present invention relates to compositions and methods comprising a single viral vector comprising both a first polynucleotide comprising a constitutive promoter operably linked to a nucleic acid encoding at least one transgene, wherein one of the at least one transgenes encodes a receptor or receptor subunit, a receptor fusion protein or a fluorescent marker; and a second polynucleotide comprising an inducible promoter operably linked to a nucleic acid encoding an effector. Also provided are engineered cells comprising the viral vector and methods for generating the engineered cells comprising the viral vector. Also provided is site-specific integration of the genetic element into the a gene locus by means of a CRISPR-related system. Further provided are methods for treating a patient having a disease, a disorder or condition associated with expression of an antigen, the method comprising administering to the patient an effective amount of a composition comprising the engineered cell.
    Type: Application
    Filed: April 8, 2019
    Publication date: February 4, 2021
    Inventors: Daniel J. Powell, Anze Smole, Avery D. Posey, Donald O'Rourke, Yibo Yin, Carl June, Philipp Romel
  • Publication number: 20200370013
    Abstract: The present disclosure provides modified immune cells or precursors thereof (e.g. modified T cells) comprising a chimeric cell surface sialidase or a variant sialidase precursor protein. Compositions and methods of treatment are also provided.
    Type: Application
    Filed: May 20, 2020
    Publication date: November 26, 2020
    Inventors: Avery D. Posey, Tiffany King
  • Publication number: 20200306304
    Abstract: Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Avery D. Posey, Carl H. June
  • Publication number: 20190389928
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein. The CAR may comprise a mutant CD28 costimulatory domain.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 26, 2019
    Inventors: Avery D. Posey, Sonia Guedan Carrio
  • Patent number: 10501519
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 10, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, John Scholler, Avery D. Posey, Jr.